Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ALEXANDER LAZAR and ANTHONY PAUL CONLEY.
ALEXANDER LAZAR
Connection Strength
2.396
ANTHONY PAUL CONLEY
  1. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohort. Rare Tumors. 2024; 16:20363613241271669.
    View in: PubMed
    Score: 0.246
  2. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes. Clin Cancer Res. 2023 12 01; 29(23):4844-4852.
    View in: PubMed
    Score: 0.234
  3. Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma. J Immunother. 2022 10 01; 45(8):374-378.
    View in: PubMed
    Score: 0.214
  4. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).
    View in: PubMed
    Score: 0.171
  5. Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Curr Oncol Rep. 2018 03 26; 20(5):37.
    View in: PubMed
    Score: 0.158
  6. Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. J Glob Oncol. 2018 09; 4:1-6.
    View in: PubMed
    Score: 0.150
  7. Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res. 2017; 7:11.
    View in: PubMed
    Score: 0.150
  8. Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma? Am J Clin Oncol. 2024 Sep 03.
    View in: PubMed
    Score: 0.062
  9. Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas. Mol Cancer Ther. 2024 Jul 02; 23(7):1057-1065.
    View in: PubMed
    Score: 0.061
  10. High-Grade Pleomorphic Sarcomas Treated with Immune Checkpoint Blockade: The MD Anderson Cancer Center Experience. Cancers (Basel). 2024 May 01; 16(9).
    View in: PubMed
    Score: 0.060
  11. Utility of Clinical Next Generation Sequencing Tests in KIT/PDGFRA/SDH Wild-Type Gastrointestinal Stromal Tumors. Cancers (Basel). 2024 Apr 27; 16(9).
    View in: PubMed
    Score: 0.060
  12. A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Apr; 5(4):625-641.
    View in: PubMed
    Score: 0.059
  13. The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications. Clin Cancer Res. 2023 11 14; 29(22):4669-4678.
    View in: PubMed
    Score: 0.058
  14. Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma. HGG Adv. 2023 10 12; 4(4):100224.
    View in: PubMed
    Score: 0.057
  15. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
    View in: PubMed
    Score: 0.056
  16. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol. 2022; 12:1008484.
    View in: PubMed
    Score: 0.054
  17. Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels. Front Oncol. 2022; 12:997506.
    View in: PubMed
    Score: 0.054
  18. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial. Lancet Oncol. 2022 09; 23(9):1156-1166.
    View in: PubMed
    Score: 0.053
  19. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. Cancer. 2022 09 15; 128(18):3383-3391.
    View in: PubMed
    Score: 0.053
  20. The immune microenvironment of uterine adenosarcomas. Clin Sarcoma Res. 2020; 10:5.
    View in: PubMed
    Score: 0.045
  21. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172.
    View in: PubMed
    Score: 0.045
  22. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020 02 21; 11(1):1008.
    View in: PubMed
    Score: 0.045
  23. Extraskeletal Myxoid Chondrosarcomas: Combined Modality Therapy With Both Radiation and Surgery Improves Local Control. Am J Clin Oncol. 2019 10; 42(10):744-748.
    View in: PubMed
    Score: 0.044
  24. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. Int J Gynecol Cancer. 2018 09; 28(7):1297-1310.
    View in: PubMed
    Score: 0.041
  25. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
    View in: PubMed
    Score: 0.040
  26. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist. 2017 10; 22(10):1271-1277.
    View in: PubMed
    Score: 0.038
  27. MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. Br J Radiol. 2016; 89(1058):20150308.
    View in: PubMed
    Score: 0.034
  28. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res. 2013 May 11; 3(1):7.
    View in: PubMed
    Score: 0.028
  29. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011 Jan; 67 Suppl 1:S15-24.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.